Compare MGRC & DYN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MGRC | DYN |
|---|---|---|
| Founded | 1979 | 1984 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Diversified Commercial Services | Medicinal Chemicals and Botanical Products |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.9B | 2.8B |
| IPO Year | 1995 | 2020 |
| Metric | MGRC | DYN |
|---|---|---|
| Price | $112.98 | $14.23 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 3 | 17 |
| Target Price | ★ $145.40 | $35.73 |
| AVG Volume (30 Days) | 135.9K | ★ 3.0M |
| Earning Date | 10-28-2026 | 11-04-2026 |
| Dividend Yield | ★ 1.75% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 2.47 | N/A |
| Revenue | ★ $944,235,000.00 | N/A |
| Revenue This Year | $2.01 | N/A |
| Revenue Next Year | $4.41 | N/A |
| P/E Ratio | $45.79 | ★ N/A |
| Revenue Growth | ★ 3.65 | N/A |
| 52 Week Low | $94.99 | $14.00 |
| 52 Week High | $125.83 | $27.31 |
| Indicator | MGRC | DYN |
|---|---|---|
| Relative Strength Index (RSI) | 46.95 | 27.68 |
| Support Level | $109.63 | N/A |
| Resistance Level | $118.53 | $19.46 |
| Average True Range (ATR) | 2.56 | 0.74 |
| MACD | -0.19 | 0.16 |
| Stochastic Oscillator | 18.17 | 4.29 |
McGrath RentCorp is a diversified business-to-business rental company with three rental divisions: relocatable modular buildings, portable storage containers, and electronic test equipment. It comprises four reportable business segments, namely the Modular Building segment (Mobile Modular), which generates maximum revenue; the Portable Storage segment (Portable Storage); the Electronic Test Equipment segment (TRS-RenTelco); and its classroom manufacturing business (Enviroplex), which sells modular buildings used as classrooms in California. The company generates its revenues mainly from the rental of its equipment under operating leases, with sales of equipment occurring in the normal course of business.
Dyne Therapeutics Inc is a clinical-stage neuromuscular disease company focused on discovering and advancing life-transforming therapeutics for people living with genetically driven neuromuscular diseases. Its FORCE platform develops targeted therapeutics that are designed to overcome limitations in delivery to muscle tissue and the central nervous system, or CNS. Its FORCE platform therapeutics consist of a payload that is rationally designed to target the genetic basis of the disease being treated, a linker, and an antigen-binding fragment that attaches to the payload using the linker. Its Pipeline includes DYNE-101, DYNE-251, DYNE-302, and DYNE-401.